Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort : is there an advantage with early use?
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE).
METHODS: This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed at baseline and after 6 and 12 months and organ damage at baseline and at the last visit.
RESULTS: From 422 patients followed in the Pisa SLE cohort, 102 patients received BEL and were included and 22 (21.6%) were immunosuppressant (IS)-naïve. Lupus Low Disease Activity State (LLDAS) with a glucocorticoid (GC) dosage ≤5 mg/day (LLDAS5) and remission were achieved by 47% and 38% of patients at 6 months, and by 75% and 66% at 12 months. Comparing IS-naïve patients with those who received BEL after at least one conventional IS, we did not find significant differences in baseline characteristics and in the achievement of LLDAS5 and remission. Despite at baseline we did not observe significant differences in mean GC daily dosage, IS-naïve patients were taking a significantly lower GC daily dose at 6 and 12 months. Interestingly, IS-naïve patients were more common in the most recent years.
CONCLUSIONS: Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
RMD open - 10(2024), 2 vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tani, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
73B0K5S26A |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 26.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/rmdopen-2023-003981 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370986318 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370986318 | ||
| 003 | DE-627 | ||
| 005 | 20240426234257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2023-003981 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM370986318 | ||
| 035 | |a (NLM)38609320 | ||
| 035 | |a (PII)e003981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tani, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort |b is there an advantage with early use? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE) | ||
| 520 | |a METHODS: This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed at baseline and after 6 and 12 months and organ damage at baseline and at the last visit | ||
| 520 | |a RESULTS: From 422 patients followed in the Pisa SLE cohort, 102 patients received BEL and were included and 22 (21.6%) were immunosuppressant (IS)-naïve. Lupus Low Disease Activity State (LLDAS) with a glucocorticoid (GC) dosage ≤5 mg/day (LLDAS5) and remission were achieved by 47% and 38% of patients at 6 months, and by 75% and 66% at 12 months. Comparing IS-naïve patients with those who received BEL after at least one conventional IS, we did not find significant differences in baseline characteristics and in the achievement of LLDAS5 and remission. Despite at baseline we did not observe significant differences in mean GC daily dosage, IS-naïve patients were taking a significantly lower GC daily dose at 6 and 12 months. Interestingly, IS-naïve patients were more common in the most recent years | ||
| 520 | |a CONCLUSIONS: Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological Therapy | |
| 650 | 4 | |a Lupus Erythematosus, Systemic | |
| 650 | 4 | |a Outcome Assessment, Health Care | |
| 650 | 7 | |a belimumab |2 NLM | |
| 650 | 7 | |a 73B0K5S26A |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Zucchi, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Cardelli, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Elefante, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Signorini, Viola |e verfasserin |4 aut | |
| 700 | 1 | |a Schilirò, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Cascarano, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Gualtieri, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Valevich, Anastasiya |e verfasserin |4 aut | |
| 700 | 1 | |a Puccetti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Carli, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Stagnaro, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Mosca, Marta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 10(2024), 2 vom: 12. Apr. |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:2 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2023-003981 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 2 |b 12 |c 04 | ||